Table 2. Nasal and sputum eosinophilia reduction.
| Variable | Immunotherapy group (n = 53) | Drug only group (n = 19) | p-value† | |||||
|---|---|---|---|---|---|---|---|---|
| No. | Mean±SD | Median (range) | No. | Mean±SD | Median (range) | |||
| Nasal eosinophilia | ||||||||
| Baseline | 51 | 13.27±16.09 | 7 (0–74) | 17 | 8.06±20.45 | 2 (0–86) | ||
| After 3 years | 51 | 3.12±5.70 | 1 (0–36) | 17 | 4.24±6.08 | 2 (0–24) | ||
| Difference | 49 | −10.69±16.76 | −6 (−74 to 16) | 16 | −4.25±22.55 | 0.5 (−86 to 18) | 0.006 | |
| p-value‡ | 0.001 | 0.879 | ||||||
| Sputum eosinophilia | ||||||||
| Baseline | 50 | 7.18±12.74 | 2 (0–70) | 17 | 5.29±10.74 | 1 (0–42) | ||
| After 3 years | 51 | 2.75±5.30 | 1 (0–25) | 18 | 2.94±5.30 | 2.5 (0–9) | ||
| Difference | 50 | −4.38±12.99 | −1 (−70 to 19) | 17 | −2.53±9.35 | 0 (−34 to 9) | 0.276 | |
| p-value‡ | 0.003 | 0.453 | ||||||
SD, standard deviation.
†Wilcoxon rank-sum test comparing change in immunotherapy group to drug only group. ‡Wilcoxon signed-rank test comparing change within each group.